COVID-19 Vaccine for symptomatic patients
Phase 1/2 Data
October 1, 2020 (Est)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: AdCOVID phase 1/2 readout
WHAT IS THE NEXT CATALYST EVENT?
Phase 1/2 clinical trial readout
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
06-01-2020 Launch of T-COVID Trial (Page 2)
MECHANISM OF ACTION
By utilizing the Company’s proprietary intranasal vaccine technology, it is expected that AdCOVID has the potential to activate multiple arms of the immune system as shown in a recent Phase 2 clinical study with NasoVAX, an influenza vaccine candidate based on the same platform technology
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post